This inventor holds 1 USPTO granted patent, plus 4 CIPO patents. Top assignee: University of California. Active years: 1987.
Company Filing History:
Years Active: 1987
Title: Chester A Mathis: Innovator in Amyloid Imaging
Introduction
Chester A Mathis is a notable inventor based in the United States, recognized for his contributions to the field of amyloid imaging. His work focuses on developing innovative techniques for identifying patients at risk of diseases associated with amyloid deposition. Despite having no patents listed under his name, his research has significant implications for the medical community.
Latest Patents
Chester A Mathis has been involved in groundbreaking research, leading to the development of two notable patents. The first patent is titled "Use Of Thioflavin Radiolabelled Derivatives In Amyloid Imaging For Identifying Patients Prodromal To A Disease Associated With Amyloid Deposition." This invention utilizes thioflavin radiolabeled derivatives in an imaging technique to identify patients who are in the early stages of diseases linked to amyloid deposition. The second patent, "Amyloid Imaging As A Surrogate Marker For Efficacy Of Anti-Amyloid Therapies," outlines a method for assessing the effectiveness of anti-amyloid therapies. This method involves administering specific compounds to patients and imaging them to compare amyloid deposition levels before and after treatment.
Career Highlights
Chester A Mathis is affiliated with the University of Pittsburgh, where he conducts his research. His work has contributed to advancing the understanding of amyloid-related diseases and the development of diagnostic tools that can improve patient outcomes.
Collaborations
Chester has collaborated with esteemed colleagues, including William E Klunk and Yanming Wang, to further enhance the research in amyloid imaging and its applications in clinical settings.
Conclusion
Chester A Mathis is a significant figure in the field of amyloid imaging, with research that has the potential to transform how diseases associated with amyloid deposition are diagnosed and treated. His innovative approaches continue to pave the way for advancements in medical imaging and therapy efficacy assessment.